vs

Side-by-side financial comparison of ARDELYX, INC. (ARDX) and NATIONAL PRESTO INDUSTRIES INC (NPK). Click either name above to swap in a different company.

NATIONAL PRESTO INDUSTRIES INC is the larger business by last-quarter revenue ($164.0M vs $94.5M, roughly 1.7× ARDELYX, INC.). On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs 21.7%). Over the past eight quarters, NATIONAL PRESTO INDUSTRIES INC's revenue compounded faster (46.3% CAGR vs 13.6%).

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

National Presto Industries is a company founded in 1905 in Eau Claire, Wisconsin. Originally called "Northwestern Steel and Iron Works" the company changed its name to the "National Pressure Cooker Company" in 1929 and then National Presto Industries, Inc. 1953. The company originally produced pressure canners for commercial, and later home, use. Beginning in 1939, the company introduced small home-use cooking appliances. The company was admitted to the New York Stock Exchange on March 3, 1969.

ARDX vs NPK — Head-to-Head

Bigger by revenue
NPK
NPK
1.7× larger
NPK
$164.0M
$94.5M
ARDX
Growing faster (revenue YoY)
ARDX
ARDX
+5.7% gap
ARDX
27.5%
21.7%
NPK
Faster 2-yr revenue CAGR
NPK
NPK
Annualised
NPK
46.3%
13.6%
ARDX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
ARDX
ARDX
NPK
NPK
Revenue
$94.5M
$164.0M
Net Profit
$-37.6M
Gross Margin
16.9%
Operating Margin
11.4%
Net Margin
-39.8%
Revenue YoY
27.5%
21.7%
Net Profit YoY
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARDX
ARDX
NPK
NPK
Q1 26
$94.5M
Q4 25
$125.2M
$164.0M
Q3 25
$110.3M
$115.5M
Q2 25
$97.7M
$120.4M
Q1 25
$74.1M
$103.6M
Q4 24
$116.1M
$134.7M
Q3 24
$98.2M
$91.8M
Q2 24
$73.2M
$85.1M
Net Profit
ARDX
ARDX
NPK
NPK
Q1 26
$-37.6M
Q4 25
$-407.0K
Q3 25
$-969.0K
$5.3M
Q2 25
$-19.1M
$5.2M
Q1 25
$-41.1M
$7.6M
Q4 24
$4.6M
Q3 24
$-809.0K
$8.1M
Q2 24
$-16.5M
$6.1M
Gross Margin
ARDX
ARDX
NPK
NPK
Q1 26
Q4 25
91.3%
16.9%
Q3 25
96.4%
13.9%
Q2 25
87.3%
15.4%
Q1 25
83.4%
17.5%
Q4 24
84.3%
24.3%
Q3 24
84.0%
18.8%
Q2 24
87.1%
17.3%
Operating Margin
ARDX
ARDX
NPK
NPK
Q1 26
Q4 25
4.1%
11.4%
Q3 25
4.2%
5.6%
Q2 25
-14.7%
5.1%
Q1 25
-49.0%
8.8%
Q4 24
7.0%
17.3%
Q3 24
2.3%
10.0%
Q2 24
-18.6%
7.5%
Net Margin
ARDX
ARDX
NPK
NPK
Q1 26
-39.8%
Q4 25
-0.3%
Q3 25
-0.9%
4.6%
Q2 25
-19.5%
4.3%
Q1 25
-55.5%
7.3%
Q4 24
4.0%
Q3 24
-0.8%
8.8%
Q2 24
-22.5%
7.1%
EPS (diluted)
ARDX
ARDX
NPK
NPK
Q1 26
$-0.15
Q4 25
$-0.01
Q3 25
$0.00
Q2 25
$-0.08
Q1 25
$-0.17
Q4 24
$0.01
Q3 24
$0.00
Q2 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARDX
ARDX
NPK
NPK
Cash + ST InvestmentsLiquidity on hand
$238.1M
$3.8M
Total DebtLower is stronger
$203.5M
Stockholders' EquityBook value
$148.6M
$395.1M
Total Assets
$504.5M
$500.7M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARDX
ARDX
NPK
NPK
Q1 26
$238.1M
Q4 25
$68.0M
$3.8M
Q3 25
$42.7M
$4.6M
Q2 25
$90.0M
$4.8M
Q1 25
$30.8M
$5.5M
Q4 24
$64.9M
$22.7M
Q3 24
$47.4M
$33.2M
Q2 24
$41.9M
$53.4M
Total Debt
ARDX
ARDX
NPK
NPK
Q1 26
$203.5M
Q4 25
$202.8M
Q3 25
$202.1M
Q2 25
$201.4M
Q1 25
$151.3M
Q4 24
$150.9M
Q3 24
$100.7M
Q2 24
$100.2M
Stockholders' Equity
ARDX
ARDX
NPK
NPK
Q1 26
$148.6M
Q4 25
$166.9M
$395.1M
Q3 25
$154.3M
$379.8M
Q2 25
$139.5M
$374.1M
Q1 25
$145.7M
$368.6M
Q4 24
$173.3M
$367.6M
Q3 24
$158.3M
$346.6M
Q2 24
$147.0M
$338.1M
Total Assets
ARDX
ARDX
NPK
NPK
Q1 26
$504.5M
Q4 25
$501.6M
$500.7M
Q3 25
$486.2M
$503.8M
Q2 25
$466.8M
$471.9M
Q1 25
$410.2M
$455.3M
Q4 24
$435.8M
$453.4M
Q3 24
$367.9M
$428.9M
Q2 24
$343.5M
$418.1M
Debt / Equity
ARDX
ARDX
NPK
NPK
Q1 26
1.37×
Q4 25
1.21×
Q3 25
1.31×
Q2 25
1.44×
Q1 25
1.04×
Q4 24
0.87×
Q3 24
0.64×
Q2 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARDX
ARDX
NPK
NPK
Operating Cash FlowLast quarter
$13.9M
Free Cash FlowOCF − Capex
$12.4M
FCF MarginFCF / Revenue
7.6%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-36.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARDX
ARDX
NPK
NPK
Q1 26
Q4 25
$21.0M
$13.9M
Q3 25
$365.0K
$-24.6M
Q2 25
$-25.3M
$-10.9M
Q1 25
$-38.5M
$12.5M
Q4 24
$9.8M
$-7.6M
Q3 24
$501.0K
$-17.5M
Q2 24
$-19.4M
$-33.9M
Free Cash Flow
ARDX
ARDX
NPK
NPK
Q1 26
Q4 25
$20.6M
$12.4M
Q3 25
$209.0K
$-24.7M
Q2 25
$-26.0M
$-13.4M
Q1 25
$-38.8M
$-10.5M
Q4 24
$9.2M
$-11.3M
Q3 24
$364.0K
$-20.3M
Q2 24
$-19.5M
$-34.5M
FCF Margin
ARDX
ARDX
NPK
NPK
Q1 26
Q4 25
16.4%
7.6%
Q3 25
0.2%
-21.4%
Q2 25
-26.6%
-11.1%
Q1 25
-52.3%
-10.2%
Q4 24
7.9%
-8.4%
Q3 24
0.4%
-22.1%
Q2 24
-26.7%
-40.6%
Capex Intensity
ARDX
ARDX
NPK
NPK
Q1 26
Q4 25
0.3%
0.9%
Q3 25
0.1%
0.1%
Q2 25
0.7%
2.0%
Q1 25
0.4%
22.2%
Q4 24
0.5%
2.7%
Q3 24
0.1%
3.1%
Q2 24
0.2%
0.8%
Cash Conversion
ARDX
ARDX
NPK
NPK
Q1 26
Q4 25
Q3 25
-4.63×
Q2 25
-2.12×
Q1 25
1.64×
Q4 24
2.11×
Q3 24
-2.16×
Q2 24
-5.58×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARDX
ARDX

IBSRELA$70.1M74%
XPHOZAH$23.3M25%
Non-cash royalty revenue related to the sale of future royalties$695.0K1%
Product supply revenue$354.0K0%

NPK
NPK

Segment breakdown not available.

Related Comparisons